Active ingredientTezacaftorCat. No. P-T080-001CAS 1152311-62-0Family · Pharmaceutical analytical standards
Tezacaftor
A CFTR protein modulator for cystic fibrosis, approved in 2018 in the United States and the European Union together with ivacaftor, and since 2019 (in the US) also in a triple combination with elexacaftor and ivacaftor. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?It is a 'corrector': it helps the CFTR protein altered by the F508del mutation fold into the right shape and reach the cell surface, where it can work.
Go to the active ingredient →Active ingredientTezacaftorCat. No. P-T080-001CAS 1152311-62-0
MetaboliteTezacaftor Metabolite 1 (Mixture of Diastereomers)Cat. No. P-T080-002CAS 1432656-97-7
Isotopically labelled(S)-Tezacaftor-d4Cat. No. P-T080-003
Isotopically labelledTezacaftor-d4Cat. No. P-T080-004CAS 1961280-24-9
Impurity(S)-TezacaftorCat. No. P-T080-005CAS 1152311-99-3
ImpurityTezacaftor Impurity 1Cat. No. P-T080-006CAS 862574-88-7
ImpurityTezampanelCat. No. P-T080-007CAS 154652-83-2
ImpurityTezosentanCat. No. P-T080-008CAS 180384-57-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.